Acute Δ9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion

Pharmacology Biochemistry and Behavior

Volumn 81, Issue 1, 2005, Pages 71-77

  Gorriti, Miguel Angel ^b   Ferrer, Belén ^a   Del Arco, Ignacio ^a   Bermúdez Silva, Francisco Javier ^a   De Diego, Yolanda ^a   Fernandez Espejo, Emilio ^c   Navarro, Miguel ^b   Rodríguez De Fonseca, Fernando ^a,b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Behavior; Cannabinoids; CB1 receptors; Dopamine receptors; Locomotion; Quinpirole; Sensitization; THC

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DRONABINOL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); QUINPIROLE; TETRAHYDROCANNABINOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; CORPUS STRIATUM; DATA ANALYSIS; EXPOSURE; HYPERACTIVITY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; STIMULATION; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; MOTOR ACTIVITY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MOTOR ACTIVITY; QUINPIROLE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 19344372424     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.02.004     Document Type: Article

References (31)

1. S. Andreasson, P. Allebeck, A. Engstrom, and U. Rydberg Cannabis and schizophrenia. A longitudinal study of Swedish conscripts Lancet 2 1987 1483 1486
2. L. Arseneault, M. Cannon, J. Witton, and R.M. Murray Causal association between cannabis and psychosis: examination of the evidence Br J Psychiatry 184 2004 110 117
3. J.P. Chen, W. Paredes, J. Li, D. Smith, J. Lowinson, and E.L. Gardner Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis Psychopharmacology (Berl) 102 1990 156 162
4. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
5. B. Ferrer, N. Asbrock, S. Kathuria, D. Piomelli, and A. Giuffrida Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias Eur J Neurosci 18 2003 1607 1614
6. E.L. Gardner, and S.R. Vorel Cannabinoid transmission and reward-related events Neurobiol Dis 5 1998 502 533
7. A. Giuffrida, L.H. Parsons, T.M. Kerr, F. Rodriguez de Fonseca, M. Navarro, and D. Piomelli Dopamine activation of endogenous cannabinoid signaling in dorsal striatum Nat Neurosci 2 1999 358 363
8. A. Giuffrida, F.M. Leweke, C.W. Gerth, D. Schreiber, D. Koethe, and J. Faulhaber Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms Neuropsychopharmacology 29 2004 2108 2114
9. M. Glass, and C.C. Felder Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor J Neurosci 17 1997 5327 5333
10. M.A. Gorriti, F. Rodriguez de Fonseca, M. Navarro, and T. Palomo Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats Eur J Pharmacol 365 1999 133 142
11. C. Gueudet, V. Santucci, M. Rinaldi-Carmona, P. Soubrie, and G. Le Fur The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat Neuroreport 6 1995 1421 1425
12. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J Neurosci 11 1991 563 583
13. P. Knudsen, and T. Vilmar Cannabis and neuroleptic agents in schizophrenia Acta Psychiatr Scand 69 1984 162 174
14. F.M. Leweke, A. Giuffrida, U. Wurster, H.M. Emrich, and D. Piomelli Elevated endogenous cannabinoids in schizophrenia Neuroreport 10 1999 1665 1669
15. P. Mailleux, and J.J. Vanderhaeghen Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study J Neurochem 61 1993 1705 1712
16. Y.P. Maneuf, A.R. Crossman, and J.M. Brotchie The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease Exp Neurol 148 1997 265 270
17. S. Mato, V. Chevaleyre, D. Robbe, A. Pazos, P.E. Castillo, and O.J. Manzoni A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity Nat Neurosci 7 2004 585 586
18. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, and A.R. Schatz Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem Pharmacol 50 1995 83 90
19. J.P. Meschler, F.A. Clarkson, P.J. Mathews, A.C. Howlett, and B.K. Madras D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates J Pharmacol Exp Ther 292 2000 952 959
20. J.M. Ng Cheong Ton, G.A. Gerhardt, M. Friedemann, A.M. Etgen, G.M. Rose, and N.S. Sharpless The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study Brain Res 451 1988 59 68
21. D. Piomelli The molecular logic of endocannabinoid signalling Nat Rev Neurosci 4 2003 873 884
22. D. Piomelli, A. Giuffrida, A. Calignano, and F. Rodriguez de Fonseca The endocannabinoid system as a target for therapeutic drugs Trends Pharmacol Sci 21 2000 218 224
23. F.R. Rodriguez de Fonseca, M.A. Villanua, R.M. Munoz, O. San-Martin-Clark, and M. Navarro Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats Neuroendocrinology 61 1995 714 721
24. F. Rodriguez de Fonseca, M.R. Carrera, M. Navarro, G.F. Koob, and F. Weiss Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal Science 276 1997 2050 2054
25. F. Rodriguez de Fonseca, I. Del Arco, J.L. Martin-Calderon, M.A. Gorriti, and M. Navarro Role of the endogenous cannabinoid system in the regulation of motor activity Neurobiol Dis 5 1998 483 501
26. F. Rodriguez de Fonseca, M. Navarro, R. Gomez, L. Escuredo, F. Nava, and J. Fu An anorexic lipid mediator regulated by feeding Nature 414 2001 209 212
27. 9-tetrahydrocannabinol toxicity in rats treated for periods up to six months Toxicol Appl Pharmacol 32 1975 399 417
28. M.C. Sanudo-Pena, and J.M. Walker Effects of intrapallidal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system Synapse 28 1998 27 32
29. M.C. Sanudo-Pena, M. Force, K. Tsou, A.S. Miller, and J.M. Walker Effects of intrastriatal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system Synapse 30 1998 221 226
30. L.J. Sim, R.E. Hampson, S.A. Deadwyler, and S.R. Childers Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S] GTPgammaS autoradiography in rat brain J Neurosci 16 1996 8057 8066
31. S.J. Tsai, Y.C. Wang, and C.J. Hong Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia Psychiatr Genet 10 2000 149 151